跳至主要内容
临床试验/NCT02775162
NCT02775162已完成不适用

A Multicenter Randomized Controlled Trial to Compare the Efficacy of Ex-vivo Normothermic Machine Perfusion With Static Cold Storage in Human Liver Transplantation

OrganOx Ltd.30 个研究点 分布在 1 个国家目标入组 267 人开始时间: 2016年10月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
267
试验地点
30
主要终点
Percentage of Participants With Early Allograft Dysfunction (EAD)

研究概览

简要总结

A multicenter randomized controlled trial to compare the efficacy of ex-vivo normothermic machine profusion with static cold storage in human liver transplantation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is 18 years of age or greater
  • Subject is registered as an active recipient on the United Network for Organ Sharing (UNOS) waiting list for liver transplantation
  • Subject, or legally authorized representative, is able and willing to give informed consent and HIPAA authorization
  • Subject is able and willing to comply with all study requirements

排除标准

  • Subject requiring all of the following at the time of transplantation: oxygen therapy, inotropic support, renal replacement therapy
  • Subject has acute/fulminant liver failure
  • Subject undergoing simultaneous transplantation of more than one organ
  • Subject is pregnant or nursing
  • Concurrent enrollment in another clinical trial. Subjects enrolled in clinical trials or registries where only measurements and/or samples are taken (NO TEST DEVICE or TEST DRUG USED) are allowed to participate.

结局指标

主要结局

Percentage of Participants With Early Allograft Dysfunction (EAD)

时间窗: 7 Days

EAD is a binary outcome defined by the presence of one of the following 3 outcomes: * Serum bilirubin ≥ 10 mg/dL at day 7 post-transplant * International normalized ratio (INR) ≥ 1.6 at day 7 post-transplant * Alanine Aminotransferase (ALT) or Aspartate Transaminase (AST) \> 2000 IU/L within the first 7 days post-transplant

次要结局

  • Number of Participants With Primary Non-Function(10 Days)
  • Number of Participants With Graft Survival(6 Months)
  • Number of Participants With Subject Survival(6 Months)
  • Number of Participants With Post-Reperfusion Syndrome(1 Day)
  • Measure Biochemical Liver Function Via Bilirubin(6 Months)
  • Measure Biochemical Liver Function Via Alanine Aminotransferase (ALT)(6 Months)
  • Measure Biochemical Liver Function Via Aspartate Transaminase (AST)(6 Months)
  • Measure Biochemical Liver Function Via Alkaline Phosphatase (ALP)(6 Months)
  • Measure Biochemical Liver Function Via International Normalized Ratio (INR)(6 Months)
  • Measure Biochemical Liver Function Via Lactate(Days 1-7)
  • Number of Participants With Evidence of Ischemia-Reperfusion Injury Via Comparison of Pre-Reperfusion Biopsies to Post-Reperfusion Biopsies(1 Day)
  • Measure Biochemical Liver Function Via Gamma-Glutamyl Transferase (GGT)(6 Months)
  • Number of Participants With Biliary Investigations and Biliary Interventions(6 Months)
  • Number of Livers Randomized But Not Transplanted(1 Day)
  • Number of Livers That Did Not Experience a Safety Event(10 Days)
  • Assessment of the Health Economic Implications Via Length of ICU Stay and Length of Hospital Stay(6 Months)
  • Compare Quality of Life Via the EQ-5D-5L Quality of Life Questionnaire(6 Months)

研究者

发起方
OrganOx Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (30)

Loading locations...

相似试验